Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Licenses Rights to MicroRNA Sequences from Max Planck

NEW YORK (GenomeWeb News) - Stratagene said today that it has licensed rights to more than 150 microRNA sequences from Max Planck Innovation, the commercial arm of the Max Planck Society.
 
Under the agreement, Stratagene purchased co-exclusive rights to use the sequences to make and sell molecular diagnostic kits based on its FullVelocity platform.
 
The company said it is particularly interested in the use of microRNAs for cancer biomarker applications.
 
Max Planck Innovation said that over the past five years it has generated more than €100 million ($130 million) through technology transfer licenses.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.